KUALA LUMPUR: Yakin Splendour Global Holdings Bhd (Yakin) has formalised a strategic collaboration with Hospital UMRA and received two national recognitions from the Malaysia Book of Records through its subsidiary, Merkel Clinic Velocity.
The partnership with Hospital UMRA, a private multidisciplinary medical provider operating in Shah Alam since 2006, was sealed through a Memorandum of Understanding (MoU) signed by Yakin director Datuk Steven Lai and Hospital UMRA founder and medical director Datuk Dr Mohamed Rafi Mohammed Feizal.
Located in Shah Alam’s Section 13, Hospital UMRA serves a broad and predominantly Muslim patient community, guided by a vision to be a ‘hospital of choice’ through accessible, compassionate and consistently high‑quality care.
The partnership combines Yakin’s specialised expertise in umbilical cord-derived mesenchymal stem cell (UC-MSC) technology with Hospital UMRA’s clinical infrastructure and patient-centred healthcare services.
Both organisations aim to broaden access to advanced regenerative medicine while maintaining standards of quality, safety, clinical governance and patient care.
“Breakthrough science delivers its greatest value when it reaches the patient,” said Lai.
“Through this partnership with Hospital UMRA, we bring our UC‑MSC technology out of the laboratory and closer to patients – turning breakthrough science into real‑world healthcare solutions.
“Hospital UMRA shares our belief that advanced medicine must be delivered responsibly, compassionately, and within reach. Together, we are building a vital bridge between biotechnology innovation and trusted clinical care,” he added.
The partnership is expected to support greater knowledge exchange, clinical cooperation and public awareness surrounding regenerative medicine, while strengthening Malaysia’s capabilities in emerging areas of medical sciences.
Welcoming the partnership, Dr Mohamed Rafi noted that Hospital UMRA has always been guided by quality, integrity and patient welfare.
“Our partnership with Yakin opens the door to advanced regenerative medicine, developed and delivered within a responsible, ethically sound clinical environment. It brings us closer to realising our vision: to be the healthcare provider of choice for the Muslim community and across the Klang Valley. Innovation and compassion must move forward together – always putting patient welfare first,” he said.
Merkel Clinic Velocity secures two Malaysia Book of Records awards
Separately, Merkel Clinic Velocity secured two national honours from the Malaysia Book of Records, recognising it as Malaysia’s first physoxic mesenchymal stem cell (MSC) provider and Malaysia’s first P4 normoxic mesenchymal Stem Cell (MSC) developer.
MSCs are widely used in regenerative medicine for their potential to support tissue repair, regulate immune and inflammatory responses, and form the foundation of future therapies. Cultivating these cells reliably through P4, a key laboratory growth stage, while maintaining full potency and consistency demands exceptional technical skill, rigorous standards and precision quality control.
Lai said these two records validate the company's pursuit of excellence and its rigorous research and development mastery.
“They reflect years of capital investment, scientific rigour, and a refusal to compromise on standards. This achievement belongs to every researcher, engineer, and partner who believed Malaysia could lead on the global stage. For Yakin, these honours are not the finish line – they are the foundation for scaling our technology, expanding our pipeline, and capturing regional market share.
“We have proven that Malaysia can develop, manufacture, and deliver world‑class regenerative medicine. That is good for our industry, good for our economy, and good for the nation’s global standing,” said Lai.
Building a regional regenerative medicine ecosystem
The Hospital UMRA partnership and the two national records represent complementary pillars of Yakin’s long‑term strategy to connect laboratory innovation with clinical delivery and build national capabilities that benefit all Malaysians.
While the Hospital UMRA partnership strengthens the clinical outreach, the recognitions earned by Merkel Clinic Velocity demonstrate the group’s commitment to developing specialised regenerative medicine capabilities within the nation.
These milestones support Malaysia’s broader ambition to become a competitive regional centre for biotechnology, medical research, healthcare innovation and regenerative medicine.
Yakin remains focused on building an ecosystem where scientific innovation, responsible clinical practice and patient accessibility progress together, according to Lai.
“Malaysia has the talent, infrastructure and strategic location to become a regional leader in regenerative medicine," Lai said, adding that realising that potential requires sustained investment, strategic collaboration, and a commitment to excellence.
"Yakin is building the complete value chain, from laboratory R&D to clinical delivery, creating high-value jobs, attracting investment, and positioning Malaysia as a destination for advanced biotech care."
He said Yakin’s roadmap centres on fostering an ecosystem of collaboration, bringing together scientists, healthcare providers, regulators, and industry partners to drive standards, build trust, and unlock the sector’s full economic and social potential.
"With these milestones, Yakin has firmly established itself as Malaysia’s flagship regenerative medicine enterprise, leading through innovation, scaling through partnership, and building a national industry with global reach," he said.
